YGYincheng Gao

Yincheng Gao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yincheng Gao has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Dandan Shan

    Department of Medical Ultrasound, Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, China

    1 shared publication
  • Hui-Xiong Xu

    Department of Ultrasound, Institute of Ultrasound in Medicine and Engineering, Zhongshan Hospital, Fudan University, Shanghai, China

    1 shared publication
  • Li-Ping Sun

    Department of Medical Ultrasound, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China

    1 shared publication
  • Qiao Wang

    Department of Medical Ultrasound, Center of Minimally Invasive Treatment for Tumor, Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, Shanghai 200072, P. R. China

    1 shared publication
  • Shaoyue Li

    Department of Medical Ultrasound and Center of Minimally Invasive Treatment for Tumor, Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, Shanghai, P. R. China

    1 shared publication
  • Shengbo Wu

    Department of Ultrasound, Zhejiang Hospital, Hangzhou, Zhejiang Province 310013, P. R. China

    1 shared publication

Latest Publications

  • Open Access

    Targeting tumor-associated CCR2 + macrophages to inhibit pancreatic cancer recurrence following irreversible electroporation

    by Weichen Xu, Shaoyue Li, Xuexia Shan, Qiao Wang, Xinhua Chen, Shengbo Wu, Yincheng Gao, Dandan Shan, Shisi Ding, Weiwei Ren, et al.

    Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with pronounced resistance to conventional therapies. Irreversible electroporation (IRE) is a promising therapy for PDAC; however, its clinical efficacy is limited by a high recurrence rate. Here, using a preclinical PDAC model, we characterized the tumor immune microenvironment following insufficient IRE (iIRE) through single-cell RNA sequencing. We found that iIRE induces a CCR2 + tumor-associated macrophage (CCR2 + TAM)–mediated immunosuppressive microenvironment in residual tumors. Consequently, we developed a macrophage-based proteolipid vesicle (mPLV) coencapsulating the CCR2 antagonist PF-4136309 (PF) and gemcitabine (GEM), named PF/GEM@mPLV. Our findings suggest that PF/GEM@mPLV achieves high drug accumulation within tumors through iIRE-induced inflammation. Reduction of CCR2 + TAMs enhances antitumor immunity and improves chemotherapeutic response. PF/GEM@mPLV markedly inhibits tumor recurrence following iIRE, diminishes hepatic metastases, and prolongs survival in preclinical PDAC models. These findings uncover the role of CCR2 + TAMs in iIRE-induced immunosuppression, offering a promising strategy to enhance the clinical potential of IRE in PDAC.